Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Total Liabilities (2016 - 2026)

Organogenesis Holdings has reported Total Liabilities over the past 11 years, most recently at $164.8 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 46.41% year-over-year to $164.8 million; the TTM value through Dec 2025 reached $164.8 million, up 46.41%, while the annual FY2025 figure was $164.8 million, 46.41% up from the prior year.
  • Total Liabilities for Q4 2025 was $164.8 million at Organogenesis Holdings, up from $123.8 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $202.0 million in Q2 2022 and troughed at $99.3 million in Q1 2025.
  • A 5-year average of $168.0 million and a median of $180.1 million in 2024 define the central range for Total Liabilities.
  • On a YoY basis, Total Liabilities climbed as much as 46.41% in 2025 and fell as far as 44.96% in 2025.
  • Year by year, Total Liabilities stood at $201.9 million in 2021, then fell by 9.03% to $183.7 million in 2022, then decreased by 1.27% to $181.4 million in 2023, then crashed by 37.93% to $112.6 million in 2024, then surged by 46.41% to $164.8 million in 2025.
  • Business Quant data shows Total Liabilities for ORGO at $164.8 million in Q4 2025, $123.8 million in Q3 2025, and $99.9 million in Q2 2025.